The agency made this known in a statement issued on its website, saying that the ban is a result of the soap having Butyphenyl Methylpropional (BMHCA) content.
The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public alert, announcing a ban on the sale and use of Dex Luxury Bar Soap.
The agency made this known in a statement issued on its website, saying that the ban is a result of the soap having Butyphenyl Methylpropional (BMHCA) content.
NAFDAC said, “The product does not comply with the Cosmetic Products Regulation as it is said to contain Butyphenyl Methylpropional (BMHCA) which is prohibited in cosmetic products due to its risk of harming the reproductive system, causing harm to the health of the unborn child and may cause skin sensitization.
“As a result, a ban on the marketing of the product has been placed by some regulatory and public authorities in the EU.”
The agency gave the product details as follows: Product Name - Dex Luxury Bar Soap (No 6 Mystic Flower); Product Brand - DEX; Country of Manufacture - Turkey; Model - 11.11.22; Barcode - 8694965531 and Category - Cosmetics.
The statement added, “Although these products are not in the NAFDAC database, importers, distributors, retailers, and consumers are advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale, and use of the above-mentioned product.
“The product’s authenticity and physical condition should be carefully checked. Members of the public in possession of the product should discontinue the sale or use and submit stock to the nearest NAFDAC office.
“Healthcare professionals and consumers are advised to report any suspicion of adverse reactions, or substandard and falsified regulated products to the nearest NAFDAC office on 0800-162-3322 or via email: [email protected].
“Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the products to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med-safety application available for download on android and IOS stores or via e-mail on [email protected].”